Mitsuro Kanda
Overview
Explore the profile of Mitsuro Kanda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
353
Citations
5040
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iizuka A, Kanda M, Sato Y, Shimizu D, Umeda S, Tanaka H, et al.
Ann Surg Oncol
. 2025 Mar;
PMID: 40080367
Background: Transcriptome analysis of primary tumor tissues from esophageal squamous cell carcinoma (ESCC) patients with early postoperative distant metastasis identified nuclear receptor subfamily 0, group B, member 1 (NR0B1) as...
2.
Enhances Cancer Cell Activities and Serves as a Prognosticator in Esophageal Squamous Cell Carcinoma
Bayasgalan T, Kanda M, Sato Y, Zhu H, Hamrah M, Martinez F, et al.
Cancer Genomics Proteomics
. 2025 Feb;
22(2):306-325.
PMID: 39993802
Background/aim: Comprehensive transcriptome analysis has revealed SPOC Domain Containing 1 (SPOCD1) as a potential biomarker for esophageal squamous cell carcinoma (ESCC). However, the expression and oncological roles of SPOCD1 in...
3.
Sugino K, Shibata M, Adachi Y, Soeda I, Ichikawa T, Inaishi T, et al.
Nagoya J Med Sci
. 2025 Jan;
86(4):665-682.
PMID: 39780930
Adenylate cyclase family members have recently received attention as novel therapeutic targets. However, the significance of adenylate cyclase 9 (ADCY9) in breast cancer has not been elucidated. Here, we evaluated...
4.
Agatsuma Y, Shimizu D, Umeda S, Tanaka H, Hattori N, Hayashi M, et al.
Cancer Genomics Proteomics
. 2024 Dec;
22(1):55-69.
PMID: 39730183
Background/aim: The development of new biomarkers to predict cancer patient prognosis is expected to aid in treatment selection, contributing to improved outcomes. In this study, we extracted a candidate gene...
5.
Tanaka C, Kanda M, Misawa K, Mochizuki Y, Hattori M, Sueoka S, et al.
Ann Gastroenterol Surg
. 2024 Nov;
8(6):999-1007.
PMID: 39502727
Background: Little information is available from prospective clinical trials on the influences of surgical approaches on postoperative quality of life (QOL). We aimed to prospectively compare chronological changes in postoperative...
6.
Otsu T, Hayashi M, Fujita K, Kobayashi D, Nakagawa N, Kurimoto K, et al.
Anticancer Res
. 2024 Oct;
44(11):4709-4721.
PMID: 39477289
Background/aim: The severe malignancy of pancreatic ductal adenocarcinoma (PDAC) is mainly due to frequent local invasiveness and distant metastasis. As for local invasiveness, we previously reported that cancer-specific molecular alterations...
7.
Hamrah M, Kanda M, Sato Y, Zhu H, Bayasgalan T, Garza F, et al.
Dis Esophagus
. 2024 Sep;
37(12).
PMID: 39324651
Esophageal squamous cell carcinoma (ESCC) is recognized as one of the most aggressive cancers with a poor prognosis. Global expression profiling was conducted on primary ESCC tissues with distant metastases....
8.
Kanda M, Kasahara Y, Shimizu D, Shinozuka T, Sasahara M, Nakamura S, et al.
Br J Cancer
. 2024 Sep;
131(9):1555-1566.
PMID: 39304746
Background: The objective of this study was to develop an innovative treatment strategy utilizing antisense oligonucleotides (ASOs) that target the gene encoding protocadherin alpha 11 (PCDHA11) and to elucidate the...
9.
Booka E, Takeuchi H, Kikuchi H, Miura A, Kanda M, Kawaguchi Y, et al.
Esophagus
. 2024 Sep;
22(1):19-26.
PMID: 39242403
Background: Cricothyrotomy is a widely performed potentially life-saving treatment to secure an airway in emergencies. It is also a pneumonia-preventing treatment to secure an expectorant route in patients with difficulty...
10.
Kanda M, Takano N, Miyauchi H, Ueda K, Mizuno M, Kasahara Y, et al.
Gastric Cancer
. 2024 Aug;
27(6):1229-1241.
PMID: 39192097
Background: Peritoneal metastasis of gastric cancer is closely associated with dismal prognosis. In previous preclinical proof-of-concept studies, an amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotide (ASO), designated ASO-4733 that targets the...